President Donald Trump’s doctors said at a press conference on October 3 that the president received re-dissivir, a drug tested in the Bronx to treat patients with COVID-19, as a component of a joint study initiative between the Montefiore Health System and Albert Einstein College. Medicine.
Einstein/Montefiore was the only site in New York that participated in what is an ongoing foreign study on addiction remedy. The first iteration of the COVID-19 Adaptive Remedy (ACTT) trial began in several locations on February 21, although recruitment did not. started in the Bronx until March. Redesivir is described as a broad-spectrum experimental antiviral drug and was discovered and developed through Gilead Sciences, Inc. , of Foster City, California.
Researchers involved in the trial, and Dr. Anthony Fauci, a senior member of the White House Coronavirus Working Group, announced on April 29 that they were cautiously positive about the effects of Phase I of the study related to the drug’s ability to decrease recovery. time in treated patients, for COVID-19 and, in particular, its potential for others who have severe lung headaches due to coronavirus.
Following the announcement, as reported through Norwood News on Friday, May 1, Trump’s management announced an emergency authorization for the use of remdesivir for the coVID-19 remedy suspected or laboratory-confirmed in adults and young people hospitalized for a serious illness. Issuing an emergency use authorization is different from general FDA approval. NBC reported on October 3 that the president’s doctors will need to apply for special permission to treat him with the drug.
The time at which iteration of the trial (ACTT 2) began on 8 May to assess the protection and efficacy of redesivir, as well as baricitinib anti-inflammatory for the remedy of adults hospitalized with COVID-19.
The drug is tested through the National Institute of Allergy and Infectious Diseases (NIAID). The institute announced on August 5 that the third iteration of the trial, ACTT 3, is underway and is comparing the protection and efficacy of a regimen composed of redesivir. plus the beta-1a interferon immunomodulator in patients with COVID-19. The New York Times reported in mid-August that the effects of Phase 2 were still being evaluated. Phase 3 is expected to end on November 1, 2023.
Speaking at Walter Reed National Military Medical Center in Washington DC, where the president is a patient, his doctors said he was not receiving hydroxychloroquine and that he had also not been placed in a position of mendacity (a position in which patients are placed face down to help. lung functioning capacity). They also showed that lately I wasn’t getting oxygen.
His medical team said Thursday that he had a fever and mild cough and was exhausted. In response to a consultation on other conditions besides his weight, which can make the president more vulnerable to coronavirus, his doctors said he was in addition to being 74. years, a boy and an obese boy, sometimes he was healthy.
They added that he was in a good mood, that his important symptoms were not a fear and that they were still being monitored and that he was walking and on Saturday, October 3. He was asked through a reporter why he considered it mandatory to be admitted to the hospital, he said. Dr. Sean P. Conley: “Because he is the president of the United States. “
Later, on October 3, the president tweeted a video informing the public about his and thanking his medical team and followers.
– Donald J. Trump (@realDonaldTrump) October 3, 2020
Do you like this story? Leave your down.